Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Hepion Pharmaceuticals, Inc.HEPA · Entity 8208 | Director | February 19, 2024 | February 21, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Hepion Pharmaceuticals, Inc.
Report date February 19, 2024 · Filed February 21, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $2.56 · Expires 2034-02-19 | Direct | 88,000 |
Reported balance
After 2024-02-19 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-02-19 · Grant · Acquired 85,000 · Balance 88,000 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 19, 2024 Filed Feb 21, 2024 20:01 UTC | Hepion Pharmaceuticals, Inc. HEPA · Entity 8208 | GrantStock Options · Derivative | 85,000 | $0.00 Strike: $2.56 | $0.00 |
DisclosureSEC source: 0001493152-24-007464 · ownership.xml · derivative · entry 1 Lbiati Kaouthar · CIK 0001938708 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 88,000 Underlying: Common Stock · 85,000 shares Expires 2034-02-19 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.